Experience

Cooley Defeats Patent Infringement Suit for Vifor

August 28, 2024

Cooley successfully defeated a patent infringement suit for its client Vifor (International) AG, a pioneer in iron deficiency and anemia therapies. The Cooley IP litigation team representing Vifor was led by intellectual property (IP) litigation partners Sanya Sukduang and Jonathan Davies, with support from cyber/data/privacy partner Tiana Demas and IP litigation associates John Habibi and Bonnie Fletcher Price.

Read more

Related contacts

Sanya Sukduang
Partner, Washington, DC
Jonathan Davies
Partner, Washington, DC
Tiana Demas
Partner
John Habibi
Associate, Washington, DC

Related Practices & Industries

Liquidia Technologies Prevails in High Blood Pressure Drug Patent Litigation

June 27, 2024

Cooley successfully defeated an inter partes review on behalf of Liquidia Technologies, a biopharmaceutical company focused on the development and commercialization of products to treat pulmonary hypertension, in United Therapeutics Corp. v. Liquidia Technologies Inc., case number 22-2133, in the US Court of Appeals for the Federal Circuit, relating to Liquidia’s high blood pressure drug patent.

Read more

Related contacts

Sanya Sukduang
Partner, Washington, DC
Jonathan Davies
Partner, Washington, DC
Robert Minn
Associate, Palo Alto
Rachel Preston
Associate, Washington, DC

Related Practices & Industries

Samsung Bioepis Defeats Emergency Motion for Injunction

June 18, 2024

Cooley successfully defeated an emergency motion for injunction for Samsung in Alexion Pharmaceuticals, Inc. et al. v. Samsung Bioepis Co. Ltd. before District Judge Gregory Williams in ongoing Biologics Price Competition and Innovation Act (BPCIA) litigation for its proposed biosimilar Soliris, which is used to treat blood disorders.

Read more

Related contacts

Dr. Michelle Rhyu
Senior Counsel, Palo Alto
Daniel Knauss
Partner, Palo Alto
Jonathan Davies
Partner, Washington, DC
Orion Armon
Partner, Colorado
HanByul Chang
Associate, Palo Alto

Related Practices & Industries

Cooley Defeats Preliminary Injunction for Liquidia in Litigation With United Therapeutics

June 3, 2024

Cooley successfully defeated a preliminary injunction filed by United Therapeutics that sought to block the launch of client Liquidia’s Yutrepia (treprostinil) inhalation powder for treatment of pulmonary hypertension associated with interstitial lung disease.

Read more

Related contacts

Sanya Sukduang
Partner, Washington, DC
Jonathan Davies
Partner, Washington, DC
Phillip Morton
Partner, Washington, DC
Lauren Strosnick
Associate, Palo Alto
Robert Minn
Associate, Palo Alto
John Habibi
Associate, Washington, DC
Rachel Preston
Associate, Washington, DC

Related Practices & Industries

Cooley Secures Win for Liquidia to Launch First Product

April 5, 2024

Cooley successfully lifted a Hatch-Waxman injunction for Liquidia Technologies, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products, enabling Liquidia to launch its new drug, Yutrepia.

Read more

Related contacts

Sanya Sukduang
Partner, Washington, DC
Jonathan Davies
Partner, Washington, DC
Daniel Knauss
Partner, Palo Alto
Adam Pivovar
Partner, Washington, DC
Robert Minn
Associate, Palo Alto
Lauren Strosnick
Associate, Palo Alto
Jennifer Volk-Fortier
Associate, Washington, DC
Sam Whitt
Associate, Washington, DC
Larissa Diaz
Senior Paralegal, Washington, DC
Jeannine Douglas
Paralegal Specialist, Palo Alto
Melissa Eskola
Paralegal Specialist, Reston
Loreylys Feliciano
Paralegal Specialist, Chicago
Douglas Lyles
Senior Research Services & Access Analyst

Related Practices & Industries

Admissions and credentials

District of Columbia

Maryland

Memberships and affiliations

American Intellectual Property Law Association

Order of the Coif

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.